Successful treatment of galactorrhoea and amenorrhoea and subsequent restoration of ovarian function by a new ergot alkaloid 2-brom-alpha-ergocryptine.
D015068:17-Ketosteroids / Q000652:urine; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D000818:Animals; D001681:Biological Assay; D001966:Bromine; D003429:Cross Reactions; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D004967:Estrogens / Q000652:urine; D005260:Female; D005951:Glucose Tolerance Test; D006062:Gonadotropins / Q000652:urine; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006914:Hydroxysteroids / Q000652:urine; D007328:Insulin / Q000494:pharmacology; D007775:Lactation Disorders / Q000150:complications / Q000188:drug therapy*; D008598:Menstruation / Q000187:drug effects; D001523:Mental Disorders / Q000209:etiology; D051379:Mice; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D011276:Pregnanediol / Q000652:urine; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay; D013960:Thyroid Function Tests; D013997:Time Factors
D015068:17-Ketosteroids; D004876:Ergot Alkaloids; D004967:Estrogens; D006062:Gonadotropins; D006914:Hydroxysteroids; D007328:Insulin; D011388:Prolactin; D011276:Pregnanediol; D001966:Bromine; D006854:Hydrocortisone